Thursday January 17, 2019

New Therapy for Drug-Resistant Skin Cancer Suggested by Researchers

A team of researchers has managed to exploit a vulnerability in melanoma or skin cancer that develops resistance to a targeted therapy, providing a potential new therapeutic strategy to selectively kill the drug-resistant cancer cells.

0
//
The reason for increased bleeding is not known. It may be because rivaroxaban is more 'potent', the paper published in the Journal of Clinical Oncology said. (IANS)
Representational image, pixabay

A team of researchers has managed to exploit a vulnerability in melanoma or skin cancer that develops resistance to a targeted therapy, providing a potential new therapeutic strategy to selectively kill the drug-resistant cancer cells.

The study has shown that when cancer cells develop drug resistance, they also acquire a new vulnerability, the Xinhua reported.

The researchers, led by Rene Bernards of the Netherlands Cancer Institute and Oncode Institute in Denmark, exposed this new vulnerability in melanoma that has developed resistance to treatment with a BRAF inhibitor — a targeted therapy that blocks a signalling pathway in the cancer cell through which it gets the message to keep on dividing.

Since more than half of all melanoma patients have a mutation in this BRAF gene, the BRAF-inhibitor stops tumour growth in those patients.

But within a few months, the tumour cell adapts the original signalling pathway and becomes active again, and even hyperactive.

The researchers, however, found that the hyperactive resistant melanoma cells produced large amounts of reactive oxygen species, but cancer cells still sensitive to the drug did not do so.

Combining the new compound with vitamin D allowed certain protective genes to be expressed at much higher levels than they are in diseased cells.
Representational image, pixabay

The study, published in the journal Cell, found that the abundance of free radicals caused the resistant melanoma cells to stop dividing, but they did not die.

When tested on mice along with an existing drug, vorinostat, which is known to stimulate the production of free oxygen radicals, the researchers saw tumours shrink under the influence of the drug, the report said.

This laid the foundation for a new therapeutic strategy: Treating patients with BRAF-mutated melanoma, as usual, with signal pathway inhibitors.

When the tumour becomes resistant, stop giving those inhibitors and immediately treat the patients with vorinostat to kill the resistant cancer cells.

Also Read: Leukemia Progression in Kids Can be Delayed Through Bone Density Treatment

“It is not a combination drug. It is very important that you first stop the signalling pathway inhibitors because they suppress the free radicals and thus eliminate the effects of vorinostat,” Bernards said. (IANS)

Next Story

Risk Of Suicide Quadruples With Cancer: Study

The results could be used to help identify patients who may be at a higher risk for suicide and help health care providers tailor their treatments accordingly.

0
A Family In Delhi Commits Suicide To Thank God: Police Reports
While the risk of suicide decreases five years after a diagnosis, the risk remains high for patients with Hodgkin lymphoma and testicular cancer.

People with cancer are over four times more likely to commit suicide than people without the deadly disease, finds a study.

According to researchers from the Penn State Cancer Institute in Pennsylvania, while a lot of progress has been made in treating cancer, not as much research has been put into how cancer affects patients mentally and emotionally.

“Even though cancer is one of the leading causes of death, most cancer patients do not die from cancer, the patients usually die of another cause,” said Nicholas Zaorsky, radiation oncologist at the Penn State Cancer Institute.

“There are multiple competing risks for death, and one of them is suicide. Distress and depression can arise from cancer diagnosis, treatment, financial stress, and other causes. Ultimately, distress and depression may lead to suicide. Our goal was to quantify the risk of suicide among cancer patients,” he added.

Breast Cancer
Chemists develop unique disease-fighting ‘nano-grenades’. VOA

The study, published in the Nature Communications journal, the team compared the risk of suicide in eight million patients who had been diagnosed with cancer and those without.

They found that among people with cancer, males, patients who were diagnosed at a younger age, patients with lung, head, neck and testicular cancer, and lymphomas were more likely to commit suicide.

While the risk of suicide decreases five years after a diagnosis, the risk remains high for patients with Hodgkin lymphoma and testicular cancer.

“Treatments for some cancers — like leukemia and testicular cancer among adolescents and young adults, for example — can decrease a patient’s fertility, and that seems to be one of the risks for suicide in the long term,” Zaorsky said.

Also Read: Here’s What Causes Cancer in Children

“In contrast, elderly patients who are diagnosed with lung, prostate and head and neck cancers, are at an increased risk of suicide for the remainder of their life.”

The results could be used to help identify patients who may be at a higher risk for suicide and help health care providers tailor their treatments accordingly. (IANS)